The pharmaceutical industry’s ability to evolve alongside innovations in technology and science increases with the incorporation of digital systems and redesigned data collectors. Pharma 4.0™ is a trending industry initiative that highlights the impact and benefit of digitalisation in pharma operations and production. Digitalisation of pharma manufacturing can propel the industry forward and facilitate technological, economical, and logistical advancement.
There are very different perspectives and drivers to Pharma 4.0™ for the different stakeholders:
The 2019 ISPE Europe Pharma 4.0™ Conference is an interactive forum where top business leaders and CEOs of the industry will discuss their strategic plans for the future of pharmaceutical engineering with the implementation of digitalisation.
The two-day event will answer questions like:
Unlike other huge events, you'll have the opportunity to connect directly with knowledgeable presenters representing leading organisations, including FDA, GSK, LifeBee, MHRA, Merck, Siemens UK, Werum IT Solutions, and more.
Register today for the 2019 ISPE Europe Pharma 4.0™ Conference to stay on track with the latest evolutions on the Pharma 4.0™ topic to successfully implement strategies for your company. Come early and take advantage of in-depth training on 18–19 November to take a deeper dive into three critical areas of pharma manufacturing.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...